Center of Hope at Renown Medical Center

Summary

Center of Hope at Renown Medical Center is a medical facility located in Reno, Nevada. This center is recognized for care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Uterine Cancer, Ovarian Carcinoma and other specialties. Center of Hope at Renown Medical Center is involved with conducting 39 clinical trials across 73 conditions. There are 1 research doctors associated with this hospital, such as Peter Lim.

Top PIs

Clinical Trials running at Center of Hope at Renown Medical Center

Ovarian Cancer

Fallopian Tube Cancer

Endometrial Cancer

Cervical Cancer

Mixed Mullerian Tumor

Peritoneal Cancer

Cancer

Peritoneal Neoplasm

Serous Cystadenocarcinoma

Uterine Carcinoma

Rina-S

for Ovarian Cancer

This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo.

Recruiting

2 awards

Phase 3

4 criteria

Olvi-Vec + Chemotherapy

for Ovarian Cancer

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.

Recruiting

2 awards

Phase 3

7 criteria

Mirvetuximab + Bevacizumab

for Ovarian Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Recruiting

2 awards

Phase 3